Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
#Acquisition #Management Changes
Nov 22, 2022
www.prnewswire.com
Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation
#Customers
Jul 6, 2021
www.globenewswire.com
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
#Acquired-by #Management Changes
Dec 2, 2020
www.tmcnet.com
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
undefined
Aug 4, 2020
www.globenewswire.com
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
#Customers #Partners
Jul 21, 2020
www.globenewswire.com
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies
#Partners
May 18, 2020
www.globenewswire.com
Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.
#Management Changes
Mar 12, 2020
www.finsmes.com
Biosight Secures $19M in Series C Funding - FinSMEs
#Investment
Nov 19, 2019
www.prnewswire.com
Biosight Announces Data to be Presented at ASH 2019 Annual Meeting
#Investment
Jun 4, 2019
www.prnewswire.com
Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia
#Investment
Jul 15, 2018
www.calcalistech.com
Following FDA Clearance, BioSight to Launch Clinical Trial for Treatment of Leukemia
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
#Acquisition #Management Changes
Nov 22, 2022
www.prnewswire.com
Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation
#Customers
Jul 6, 2021
www.globenewswire.com
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
#Acquired-by #Management Changes
Dec 2, 2020
www.tmcnet.com
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
undefined
Aug 4, 2020
www.globenewswire.com
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
#Customers #Partners
Jul 21, 2020
www.globenewswire.com
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies
#Partners
May 18, 2020
www.globenewswire.com
Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.
#Management Changes
Mar 12, 2020
www.finsmes.com
Biosight Secures $19M in Series C Funding - FinSMEs
#Investment
Nov 19, 2019
www.prnewswire.com
Biosight Announces Data to be Presented at ASH 2019 Annual Meeting
#Investment
Jun 4, 2019
www.prnewswire.com
Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia
#Investment
Jul 15, 2018
www.calcalistech.com
Following FDA Clearance, BioSight to Launch Clinical Trial for Treatment of Leukemia